The SCRIPPS trial - Catheter-based radiotherapy to inhibit coronary restenosis

The SCRIPPS trial is a randomized, double-blind, placebo-controlled trial e valuating the impact of gamma radiation to inhibit in-stent restenosis, Fif ty-five patients mere enrolled; twenty-six were assigned to receive cathete r-based radiation with Ir-192 and 29 were treated with placebo. Angiographi c restenosis in the Ir-192-treated patients was significantly reduced at si x months (17% vs. 54%; p = 0.01), with the results sustained at 3-year foll ow-up (33.3% vs. 63.6%; p < 0.05). Likewise, the composite clinical endpoin t of death, myocardial infarction or target lesion revascularization was al so commensurately lower in the treated group as compared to the placebo gro up (23.1% vs. 55.2%; p = 0.01), Late angiography revealed no perforation, a neurysm or pseudoaneurysm or special safety issues unique to radiotherapy.